Meiji Holdings Co. Ltd.

03/22/2024 | Press release | Distributed by Public on 03/22/2024 00:09

Meiji Seika Pharma Presents Positive Findings from Phase III Study of Belumosudil, Selective ROCK2 Inhibitor, in Patients With Steroid-Dependent/Resistant cGVHD at JSTCT2024 in[...]